Dr. Moore is Co-Founder of ViTAA Medical Solutions and serves as its Chief Medical Officer. He is a Fellow of the Royal College of Surgeons of Canada and a Fellow of the American College of Surgeons and a member of the Canadian Society for Vascular Surgery, where he has previously served as the Research Chair, as well as the Society for Vascular Surgery. He has previously served two terms as President of Vascular Surgery for the Alberta Medical Association, as well as Division Chief of Vascular Surgery for the Calgary Health Region and has a cross appointment with the Schulich School of Engineering at the University of Calgary, with multiple published research studies related to complex Aortic Aneurysm Repair, Vascular Hemodynamics and Vascular Imaging.
ViTAA Medical Solutions is pioneering AI solutions within the vascular space with an initial focus on changing the standard of care for aortic aneurysm disease. With expected regulatory approval in 2024, its first commercial product RAW™ (Regional Areas of Weakness) Maps is available as part of the ViTAA Registry which has been launched in 8 North American sites as well as ViTAA’s Research Use Only Program consisting of 25 participating US Aortic Centers
Dr. Moore is Co-Founder of ViTAA Medical Solutions and serves as its Chief Medical Officer. He is a Fellow of the Royal College of Surgeons of Canada and a Fellow of the American College of Surgeons and a member of the Canadian Society for Vascular Surgery, where he has previously served as the Research Chair, as well as the Society for Vascular Surgery. He has previously served two terms as President of Vascular Surgery for the Alberta Medical Association, as well as Division Chief of Vascular Surgery for the Calgary Health Region and has a cross appointment with the Schulich School of Engineering at the University of Calgary, with multiple published research studies related to complex Aortic Aneurysm Repair, Vascular Hemodynamics and Vascular Imaging.
ViTAA Medical Solutions is pioneering AI solutions within the vascular space with an initial focus on changing the standard of care for aortic aneurysm disease. With expected regulatory approval in 2024, its first commercial product RAW™ (Regional Areas of Weakness) Maps is available as part of the ViTAA Registry which has been launched in 8 North American sites as well as ViTAA’s Research Use Only Program consisting of 25 participating US Aortic Centers
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy